Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3650 studies found for:    "Endocrine Gland Neoplasms"
Show Display Options
Rank Status Study
21 Active, not recruiting Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
Conditions: Medullary Thyroid Carcinoma;   Multiple Endocrine Neoplasia Type 2A;   Multiple Endocrine Neoplasia Type 2B
Intervention: Drug: Vandetanib
22 Recruiting Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Multiple Endocrine Neoplasia Type 1;   Pancreatic Neuroendocrine Carcinoma
Interventions: Radiation: Computed Tomography Perfusion Imaging;   Other: Laboratory Biomarker Analysis;   Biological: Ziv-Aflibercept
23 Completed Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
Conditions: Medullary Thyroid Carcinoma;   Multiple Endocrine Neoplasia Type 2
Intervention:
24 Recruiting Studies of Inherited Diseases of Metabolism
Conditions: Hypercalcemia;   Hyperparathyroidism;   Multiple Endocrine Neoplasia
Intervention:
25 Recruiting Efficacy and Safety of Radiofrequency Ablation in Pancreatic Neuroendocrine and Cystic Tumor
Conditions: Pancreatic Tumor;   Endocrine Tumor;   Neoplasms, Cystic, Mucinous, and Serous
Intervention: Procedure: Radiofrequency Ablation under EUS
26 Active, not recruiting Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
Conditions: Multiple Endocrine Neoplasia;   Recurrent Thyroid Gland Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Sorafenib Tosylate
27 Terminated Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia
Conditions: Colon Tumors;   Rectum Tumors;   Appendix Tumors;   Peritoneum Tumors;   Endocrine Tumors
Intervention: Drug: Oxaliplatin and irinotecan
28 Not yet recruiting Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment
Condition: Pancreatic Neuroendocrine Tumors in MEN1
Intervention: Drug: Somatostatin-Analog
29 Withdrawn Pasireotide Treatment for Neuroendocrine Tumor
Condition: Gastro-enteropancreatic Neuroendocrine Tumor
Interventions: Drug: Pasireotide;   Drug: Diazoxide
30 Completed Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neoplastic Syndrome
Interventions: Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
31 Completed Vancomycin Associated Red Man Syndrome (RMS)
Condition: Red Man Syndrome
Intervention:
32 Recruiting Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies
Conditions: Sarcoma;   Endocrine Tumors;   Neuroblastoma;   Retinoblastoma;   Renal Cancer
Intervention:
33 Recruiting Tumor Bank for Tissue Samples
Conditions: Ovarian Neoplasms;   Breast Neoplasms;   Colorectal Neoplasms;   Neoplasms of the Female Genitalia;   Lung Neoplasms;   Endocrine Gland Neoplasms
Interventions: Other: Tumor tissue collection;   Other: Sampling of ascites and pleural effusion;   Other: Collecting urine samples;   Other: Collecting saliva sample;   Other: Collecting sputum;   Other: Collecting stool samples;   Other: Lavage/Irrigation
34 Recruiting Tumor Bank for Blood Samples
Conditions: Ovarian Neoplasms;   Breast Neoplasms;   Colorectal Neoplasms;   Neoplasms of the Female Genitalia;   Lung Neoplasms;   Endocrine Gland Neoplasms
Intervention: Other: Blood collection
35 Completed High Dose Somatostatin Analogues in Neuroendocrine Tumors
Conditions: Respiratory Tract Neoplasms;   Thymic Neoplasms;   Pancreatic Neoplasms;   Gastrointestinal Neoplasms;   Multiple Endocrine Neoplasia
Intervention: Drug: Octreotide-LAR
36 Not yet recruiting Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Conditions: Functional Pancreatic Neuroendocrine Tumor;   Malignant Somatostatinoma;   Merkel Cell Carcinoma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Carcinoid Tumor;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2A;   Multiple Endocrine Neoplasia Type 2B;   Neuroendocrine Neoplasm;   Non-Functional Pancreatic Neuroendocrine Tumor;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Merkel Cell Carcinoma;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Adrenal Cortex Carcinoma;   Stage III Thyroid Gland Medullary Carcinoma;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Adrenal Cortex Carcinoma;   Stage IV Merkel Cell Carcinoma;   Stage IVA Thyroid Gland Medullary Carcinoma;   Stage IVB Thyroid Gland Medullary Carcinoma;   Stage IVC Thyroid Gland Medullary Carcinoma;   Thymic Carcinoid Tumor;   VIP-Producing Neuroendocrine Tumor;   Well Differentiated Adrenal Cortex Carcinoma;   Zollinger Ellison Syndrome
Interventions: Drug: Capecitabine;   Drug: Temozolomide;   Drug: Veliparib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
37 Completed A Study of Trabectedin in Patients With Advanced Ovarian Cancer
Conditions: Ovarian Neoplasms;   Endocrine Gland Neoplasms;   Neoplasms by Site;   Neoplasms;   Ovarian Diseases;   Adnexal Diseases;   Genital Diseases, Female
Interventions: Drug: Trabectedin;   Drug: Dexamethasone
38 Completed Assessing the Patient Experience in Cancer Care
Conditions: Brain Neoplasm;   Breast Neoplasm;   Endocrine Gland Neoplasm;   Gastrointestinal Neoplasm;   Genitourinary Neoplasm;   Gynecological Neoplasm;   Head and Neck Neoplasm;   Lung Neoplasm;   Melanoma;   Sarcoma
Intervention:
39 Active, not recruiting Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Conditions: Pancreatic Neoplasms;   Digestive System Neoplasms;   Neoplasms by Site;   Neoplasms;   Endocrine Gland Neoplasms;   Pancreatic Diseases;   Digestive System Diseases;   Endocrine System Diseases;   Gemcitabine;   Antimetabolites, Antineoplastic
Interventions: Drug: nab-Paclitaxel 125 mg/m2;   Drug: gemcitabine 1000 mg/m2
40 Recruiting Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Conditions: Neoplasms;   Neoplasms, Glandular and Epithelial;   Neoplasms by Histologic Type;   Bronchial Neoplasms;   Lung Neoplasms;   Respiratory Tract Neoplasms;   Thoracic Neoplasms;   Digestive System Neoplasms;   Endocrine Gland Neoplasms;   Carcinoma, Non-Small-Cell Lung;   Lung Diseases;   Breast Diseases;   Renal Neoplasm;   Solid Tumors
Interventions: Drug: Entinostat;   Drug: Pembrolizumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.